Generic Name and Formulations:
Potassium citrate 5mEq (540mg), 10mEq (1080mg), 15mEq (1620mg); tabs.
Mission Pharmacal Company
Indications for UROCIT-K:
Renal tubular acidosis with calcium stones. Hypocitraturic calcium oxalate nephrolithiasis. Uric acid lithiasis.
Take within 30 minutes of meals or bedtime snack. Adjust based on urinary citrate levels and/or pH. Urinary citrate <150mg/day: 30mEq twice daily or 20mEq 3 times daily. Urinary citrate >150mEq/day: 15mEq twice daily or 10mEq 3 times daily. Max 100mEq/day.
See literature. Hyperkalemia or predisposing conditions. GI narrowing or stricture, delayed gastric emptying or predisposing conditions. Peptic ulcer disease. UTI. Renal insufficiency (GFR <0.7mL/kg per minute).
Restrict salt intake and encourage high fluid intake. Discontinue if severe vomiting, GI pain or bleeding occurs and follow-up. Monitor 24 hour urinary citrate, urinary pH, serum electrolytes, CBC, ECG, at least every 4 months; discontinue if hyperkalemia, significant rise in serum creatinine, or significant fall in hematocrit or hemoglobin occurs. Pregnancy (Cat.C). Nursing mothers.
Contraindicated with potassium-sparing diuretics, anticholinergics, other drugs that slow GI motility. Monitor digoxin. May interfere with some urinary tract antibiotics. Caution with drugs that raise serum potassium.
Hyperkalemia, GI upset, irritation, bleeding.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|